Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Alibaba Health: Healthy 2H but Margins Have Very Little Room for Improvement (Quantamental)

YSB IPO: Core Business Lacks Profitability

JD Health: Profitability Remains Under Pressure

JD Health: Minimal Impact from New Policy on Digital Healthcare

2023 High Conviction: Shift’s Growth Strategy Starting to Deliver Results

Alibaba Health: New Digital Healthcare Policy to Have Less Impact but Tumbling Margins Is Worrying

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

Alibaba Health Information Tec / Equity Bottom-Up

<ul>
<li>Alibaba Health reported 1HFY03/2023 results on Monday. Revenue increased 22.9% YoY to RMB11.5bn and reported an adjusted net profit of RMB350m vs net loss of RMB283m reported in 1HFY03/2022.</li>
<li>Adjusted operating loss for the quarter decreased to RMB30m compared to RMB586m reported in the same quarter last year.</li>
<li>Ali Health’s fulfilment and S&amp;M costs were the highest among peers and cutting down these costs has helped the company reduce its operating losses.</li>
</ul>


Alibaba Health reported 1HFY03/2023 results on Monday. Revenue increased 22.9% YoY to RMB11.5bn and reported an adjusted net profit of RMB350m vs net loss of RMB283m reported in 1HFY03/2022.
Adjusted operating loss for the quarter decreased to RMB30m compared to RMB586m reported in the same quarter last year.
Ali Health’s fulfilment and S&amp;M costs were the highest among peers and cutting down these costs has helped the company reduce its operating losses.


Ping An Healthcare and Technology (1833 HK)

Alibaba Health 1H: Cost Enhancements Support Margins but Sustainabaility Remains to Be Seen